CRISPR-based Casgevy is made accessible in England following NICE guidance
The gene editing therapy will now be accessible to NHS England patients with beta-thalassemia, potentially replacing lifelong transfusions.
The gene editing therapy will now be accessible to NHS England patients with beta-thalassemia, potentially replacing lifelong transfusions.
What's Your Reaction?
